Decreased CSF levels of β-amyloid peptides (Aβ40, Aβ42) combined with increased levels of total tau and phosphorylated tau proteins, have diagnostic value in AD (Flaten et al., 2006; Hampel et al., 2010), for instance. Here, MAPT is linked to Alzheimer disease.